Israh Akhtar
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Israh Akhtar has a total of 18 co-authors. Here are the top co-authors by number of shared publications:
- Abhimanyu Tushir
Department of Pathology and Laboratory Medicine, Temple University Hospital, Philadelphia, PA 19140, USA
2 shared publications - Anjali Seth
Molecular Pathology Laboratory, Fox Chase Cancer Center, Department of Pathology Genomic Cancer Institute Philadelphia Pennsylvania USA
2 shared publications Jiejing Yin
Department of Pathology and Laboratory Medicine, Temple University Hospital Philadelphia, PA, USA
2 shared publications- Amandeep Aneja
Department of Pathology and Laboratory Medicine, Temple University Hospital, Philadelphia, PA, USA
1 shared publication Dina Zenezan
Temple University Hospital, Philadelphia, PA
1 shared publication- Dina Zenezan
Department of Pathology and Laboratory Medicine, Temple University Hospital Philadelphia, PA, USA
1 shared publication
Latest Publications
- Open Access
- 20 January 2025
- Published by MDPI AG in Current Issues in Molecular Biology
- Vol. 47 (1) , 66
A Case of Non-Small Cell Lung Cancer with Mutually Exclusive EGFR and KRAS Mutations
Historically, EGFR and KRAS mutations were believed to be mutually exclusive. However, over the past few years, there have been emerging case reports showing the co-existence of both mutations in a single case. The majority of these co-occurring alterations were detected in samples collected from patients with resistance to tyrosine kinase inhibitor (TKI) treatment, indicating a potential functional role in driving resistance to therapy. These co-occurring tumor genomic alterations are not necessarily mutually exclusive, and evidence suggests that multiple clonal and sub-clonal cancer cell populations can co-exist and contribute to EGFR TKI resistance. We have reported such a case of concomitant EGFR and KRAS mutation in a 64-year-old female. This case highlights the importance of continuous molecular testing in managing NSCLC, especially in cases with rare mutation profiles. The emergence of new mutations during treatment can significantly impact the course of therapy and patient outcomes. In this case, the detection of both EGFR and KRAS mutations guided the selection of an appropriate targeted therapeutic strategy, including the use of Amivantamab.
- 20 January 2025
- Published by MDPI AG in Current Issues in Molecular Biology
- Vol. 47 (1) , 66
Open AccessA Case of Non-Small Cell Lung Cancer with Mutually Exclusive EGFR and KRAS Mutations
Historically, EGFR and KRAS mutations were believed to be mutually exclusive. However, over the past few years, there have been emerging case reports showing the co-existence of both mutations in a single case. The majority of these co-occurring alterations were detected in samples collected from patients with resistance to tyrosine kinase inhibitor (TKI) treatment, indicating a potential functional role in driving resistance to therapy. These co-occurring tumor genomic alterations are not necessarily mutually exclusive, and evidence suggests that multiple clonal and sub-clonal cancer cell populations can co-exist and contribute to EGFR TKI resistance. We have reported such a case of concomitant EGFR and KRAS mutation in a 64-year-old female. This case highlights the importance of continuous molecular testing in managing NSCLC, especially in cases with rare mutation profiles. The emergence of new mutations during treatment can significantly impact the course of therapy and patient outcomes. In this case, the detection of both EGFR and KRAS mutations guided the selection of an appropriate targeted therapeutic strategy, including the use of Amivantamab.
- Open Access
- 21 November 2024
- Published by MDPI AG in Preprints.org
A Case of Non-Small Cell Lung Cancer with Mutually Exclusive EGFR and KRAS Mutations
Historically, EGFR and KRAS mutations were believed to be mutually exclusive. However, over the past few years, there have been emerging case reports showing the co-existence of both mutations in a single case. The majority of these co-occurring alterations were detected in samples collected from patients at resistance to tyrosine kinase inhibitor (TKI) treatment, indicating a potential functional role in driving resistance to therapy. These co-occurring tumor genomic alterations are not necessarily mutually exclusive, and evidence suggests that multiple clonal and sub-clonal cancer cell populations can co-exist and contribute to EGFR TKI resistance. We have reported such a case of concomitant EGFR and KRAS mutation in a 64 year old female. This case highlights the importance of continuous molecular testing in managing NSCLC, especially in cases with rare mutation profiles. The emergence of new mutations during treatment can significantly impact the course of therapy and patient outcomes. In this case, the detection of both EGFR and KRAS mutations guided the selection of an appropriate targeted therapeutic strategy, including the use of Amivantamab.
- 21 November 2024
- Published by MDPI AG in Preprints.org
Open AccessA Case of Non-Small Cell Lung Cancer with Mutually Exclusive EGFR and KRAS Mutations
Historically, EGFR and KRAS mutations were believed to be mutually exclusive. However, over the past few years, there have been emerging case reports showing the co-existence of both mutations in a single case. The majority of these co-occurring alterations were detected in samples collected from patients at resistance to tyrosine kinase inhibitor (TKI) treatment, indicating a potential functional role in driving resistance to therapy. These co-occurring tumor genomic alterations are not necessarily mutually exclusive, and evidence suggests that multiple clonal and sub-clonal cancer cell populations can co-exist and contribute to EGFR TKI resistance. We have reported such a case of concomitant EGFR and KRAS mutation in a 64 year old female. This case highlights the importance of continuous molecular testing in managing NSCLC, especially in cases with rare mutation profiles. The emergence of new mutations during treatment can significantly impact the course of therapy and patient outcomes. In this case, the detection of both EGFR and KRAS mutations guided the selection of an appropriate targeted therapeutic strategy, including the use of Amivantamab.
- 1 January 2024
- Published by e-Century Publishing Corporation in International Journal of Clinical and Experimental Pathology
- Vol. 17 (6) , 182-188
Navigating the diagnostic maze: the challenge of sclerosing pneumocytoma in frozen sections
Pulmonary Sclerosing Pneumocytoma (PSP) represents a rare benign tumor that exhibits a predisposition towards females. Often asymptomatic, its identification usually occurs incidentally through imaging modalities. Histologically, PSP demonstrates features consistent with pneumocytic differentiation and possesses a dual-cell population. However, in rare instances it may demonstrate pleural invasion or lymph node metastasis. Diagnosing PSP through small biopsy or frozen section presents considerable challenges attributed to its heterogeneous growth patterns and striking similarity to well-differentiated pulmonary adenocarcinoma. We report a case of PSP in a 57-year-old female smoker, presenting as a slow-growing 2.5 cm mass that recently exhibited enlargement, as noted on computed tomography (CT) scan. The recommendation for excising the mass prompted the patient to undergo a right robotic-assisted thoracoscopic procedure, which entailed wedge resection of the right lower lobe and an intraoperative consultation. A completion right lower lobectomy was performed, accompanied by lymph node dissection, following a frozen section diagnosis indicating at least adenocarcinoma in situ. The permanent section revealed bland cuboidal cells lining papillary and sclerotic areas, with occasional atypical features such as prominent nucleoli and scattered mitotic figures. Adjacent foci of atypical adenomatous hyperplasia (AAH) were noted. Immunohistochemical (IHC) staining revealed positive Napsin A, keratin AE1/3, and CK7 in surface cells but not in round cells. Both EMA and TTF1 immunostains highlighted surface cells and scattered round cells. Elastic stain highlighted visceral pleural involvement. The combined morphology and immunoprofile supported the diagnosis of PSP. This case underscores the critical importance of accurately diagnosing slow-growing pulmonary nodules, which are increasingly detected by the widespread use of imaging for various medical conditions.
- 1 January 2024
- Published by e-Century Publishing Corporation in International Journal of Clinical and Experimental Pathology
- Vol. 17 (6) , 182-188
Navigating the diagnostic maze: the challenge of sclerosing pneumocytoma in frozen sections
Pulmonary Sclerosing Pneumocytoma (PSP) represents a rare benign tumor that exhibits a predisposition towards females. Often asymptomatic, its identification usually occurs incidentally through imaging modalities. Histologically, PSP demonstrates features consistent with pneumocytic differentiation and possesses a dual-cell population. However, in rare instances it may demonstrate pleural invasion or lymph node metastasis. Diagnosing PSP through small biopsy or frozen section presents considerable challenges attributed to its heterogeneous growth patterns and striking similarity to well-differentiated pulmonary adenocarcinoma. We report a case of PSP in a 57-year-old female smoker, presenting as a slow-growing 2.5 cm mass that recently exhibited enlargement, as noted on computed tomography (CT) scan. The recommendation for excising the mass prompted the patient to undergo a right robotic-assisted thoracoscopic procedure, which entailed wedge resection of the right lower lobe and an intraoperative consultation. A completion right lower lobectomy was performed, accompanied by lymph node dissection, following a frozen section diagnosis indicating at least adenocarcinoma in situ. The permanent section revealed bland cuboidal cells lining papillary and sclerotic areas, with occasional atypical features such as prominent nucleoli and scattered mitotic figures. Adjacent foci of atypical adenomatous hyperplasia (AAH) were noted. Immunohistochemical (IHC) staining revealed positive Napsin A, keratin AE1/3, and CK7 in surface cells but not in round cells. Both EMA and TTF1 immunostains highlighted surface cells and scattered round cells. Elastic stain highlighted visceral pleural involvement. The combined morphology and immunoprofile supported the diagnosis of PSP. This case underscores the critical importance of accurately diagnosing slow-growing pulmonary nodules, which are increasingly detected by the widespread use of imaging for various medical conditions.
- Open Access
- 4 October 2023
- Published by Elsevier in Journal of the American Society of Cytopathology
- Vol. 12 (5) , S29-S30
Challenges in Re-introducing Breast Cytology in the United States and What Can we do to Bridge the Gap: A Retrospective Review in a Safety Net Hospital
- 4 October 2023
- Published by Elsevier in Journal of the American Society of Cytopathology
- Vol. 12 (5) , S29-S30
Open AccessChallenges in Re-introducing Breast Cytology in the United States and What Can we do to Bridge the Gap: A Retrospective Review in a Safety Net Hospital
- 9 August 2023
- Published by Wiley in Cytopathology
- Vol. 34 (6) , 611-616
Hyalinising clear cell carcinoma with a novel fusion gene: Insights into the diagnosis
Hyalinising clear cell carcinoma (HCCC) is a rare salivary gland neoplasm characterised by an EWSR1::ATF1 fusion. Rare cases showing EWSR1::CREB1 rearrangements have been reported. This article presents a case of HCCC with a novel EWSR1-CREB1 fusion, diffuse eosinophilic appearance, novel cytomorphological findings, PAS-negativity, and late regional and distant lymph node metastases.
- 9 August 2023
- Published by Wiley in Cytopathology
- Vol. 34 (6) , 611-616
Hyalinising clear cell carcinoma with a novel fusion gene: Insights into the diagnosis
Hyalinising clear cell carcinoma (HCCC) is a rare salivary gland neoplasm characterised by an EWSR1::ATF1 fusion. Rare cases showing EWSR1::CREB1 rearrangements have been reported. This article presents a case of HCCC with a novel EWSR1-CREB1 fusion, diffuse eosinophilic appearance, novel cytomorphological findings, PAS-negativity, and late regional and distant lymph node metastases.
- Open Access
- 12 May 2022
- Published by Elsevier in Academic Pathology
- Vol. 9 (1) , 100012
Educational Case: Immune and inflammatory diseases: A case of pulmonary sarcoidosis
- 12 May 2022
- Published by Elsevier in Academic Pathology
- Vol. 9 (1) , 100012
Open AccessEducational Case: Immune and inflammatory diseases: A case of pulmonary sarcoidosis
- 1 September 2021
- Published by Elsevier in Journal of the American Society of Cytopathology
- Vol. 10 (5) , 510-516
To whom the specimen goes: a look at how touch preparations and core needle biopsies are handled in different practices and the effect on fellowship education
- 1 September 2021
- Published by Elsevier in Journal of the American Society of Cytopathology
- Vol. 10 (5) , 510-516
To whom the specimen goes: a look at how touch preparations and core needle biopsies are handled in different practices and the effect on fellowship education
- 1 March 2021
- Published by Elsevier in Journal of the American Society of Cytopathology
- Vol. 10 (2) , 208-215
Impact of the Milan System for Reporting Salivary Gland Cytology on risk assessment when used in routine practice in a real-time setting
- 1 March 2021
- Published by Elsevier in Journal of the American Society of Cytopathology
- Vol. 10 (2) , 208-215
Impact of the Milan System for Reporting Salivary Gland Cytology on risk assessment when used in routine practice in a real-time setting